Ticagrelor approved for NHS use post-MI

The antiplatelet drug ticagrelor (Brilique) can now be prescribed on the NHS to reduce the risk of atherothrombotic events following MI.

Ticagrelor, in combination with aspirin, has been recommended by NICE as an option for preventing atherothrombotic events in adults who have had an MI and are at high risk of a further event.

Treatment should be stopped when clinically indicated or after a maximum of three years.

NICE already recommends ticagrelor, in combination with low-dose aspirin for up to 12 months, as an option to prevent atherothrombotic events in patients with acute coronary syndromes (ie, STEMI, NSTEMI or unstable angina). 

Ticagrelor targets the P2Y12 adenosine diphosphate (ADP) receptor to prevent ADP-mediated platelet activation and aggregation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases